AdvanCell

AdvanCell is a clinical-stage radiopharmaceuticals company developing a pipeline of programs harnessing the alpha-emitting isotope Lead-212 (212Pb), produced using a proprietary and scalable manufacturing process. By using 212Pb the company pursues best-in-class efficacy and safety profiles for a range of targets and indications. Their lead program ADVC001 is in Phase 2 and targets PSMA in patients with prostate cancer. The company further has a pipeline of high-value targets in development.